{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T14:10:55Z","timestamp":1788012655742,"version":"build-2784847793"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To evaluate the effects on ocular surface signs and symptoms of serial sessions of heating and vibrating eye mask followed by intense pulsed light (IPL) therapy for the treatment of dry eye disease owing to meibomian gland dysfunction (MGD).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Consecutive patients with MGD whose signs and symptoms were not satisfactorily controlled with conventional therapy were included. Patients received 3 treatments performed at day 1, 15, and 45 incorporating a session with a newly-developed eye mask (Activa, SBS Sistemi, Turin, Italy) immediately followed by IPL therapy (E\u2009&gt;\u2009Eye device, E-Swin, Paris, France). Patients were examined before the first session (T0) and 30\u2009days after the last session (T1) for the measurement of: noninvasive break-up time (NIBUT); lipid layer thickness (LLT); tear meniscus height (TMH); meibomian gland loss (MGL); tear osmolarity. Ocular discomfort symptoms were ascertained by ocular surface disease index (OSDI) questionnaire.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Thirty patients were ultimately included in the study. At T1, all objective ocular surface parameters improved significantly, except for TMH: NIBUT and LLT increased from 6.4\u2009\u00b1\u20091.7 to 8.6\u2009\u00b1\u20091.7\u2009s and from 57.7\u2009\u00b1\u200915.5 to 81.3\u2009\u00b1\u200912.0\u2009\u03bcm (all <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), while MGL and tear osmolarity decreased from 21.1\u2009\u00b1\u200917.3 to 17.0\u2009\u00b1\u200914.1% and from 302.0\u2009\u00b1\u20098.5 to 295.7\u2009\u00b1\u20096.9\u2009mOsm\/L (respectively, <jats:italic>P<\/jats:italic>\u2009=\u20090.004 and <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). In parallel, OSDI score decreased significantly from 49.8\u2009\u00b1\u200913.5 to 29.8\u2009\u00b1\u200910.6 (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). In the historical control group of patients who underwent only IPL, NIBUT, LLT, tear osmolarity and OSDI improved significantly but not MGL and TMH.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Serial sessions incorporating the application of an eye mask producing heating and vibration immediately followed by IPL therapy are able to improve all ocular surface parameters as well as ocular discomfort symptoms in MGD patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12886-022-02538-0","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T09:02:56Z","timestamp":1658221376000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Outcomes of serial sessions of Activa mask combined with intense pulsed light therapy in patients with Meibomian gland dysfunction"],"prefix":"10.1186","volume":"22","author":[{"given":"Luca","family":"Vigo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Carones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Scorcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Giannaccare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,19]]},"reference":[{"key":"2538_CR1","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1097\/ICO.0000000000001500","volume":"37","author":"G Giannaccare","year":"2018","unstructured":"Giannaccare G, Vigo L, Pellegrini M, et al. Ocular surface workup with automated noninvasive measurements for the diagnosis of Meibomian gland dysfunction. Cornea. 2018;37:740\u20135.","journal-title":"Cornea."},{"key":"2538_CR2","doi-asserted-by":"crossref","unstructured":"Knop E, Knop N, Millar T, et. al. The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland. Invest Ophthalmol Vis Sci 2011;52:1938\u20131978.","DOI":"10.1167\/iovs.10-6997c"},{"key":"2538_CR3","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1167\/iovs.10-6997a","volume":"52","author":"KK Nichols","year":"2011","unstructured":"Nichols KK, Foulks GN, Bron AJ, et al. The international workshop on meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci. 2011;52:1922\u20139.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2538_CR4","doi-asserted-by":"crossref","unstructured":"Rabensteiner DF, Aminfar H, Boldin I, et. al. The prevalence of meibomian gland dysfunction, tear film and ocular surface parameters in an Austrian dry eye clinic population. Acta Ophthalmol 2018;96:e707-e711.","DOI":"10.1111\/aos.13732"},{"key":"2538_CR5","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.survophthal.2019.08.007","volume":"65","author":"S Sabeti","year":"2020","unstructured":"Sabeti S, Kheirkhah A, Yin J, et al. Management of meibomian gland dysfunction: a review. Surv Ophthalmol. 2020;65:205\u201317.","journal-title":"Surv Ophthalmol"},{"key":"2538_CR6","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/ICO.0000000000001884","volume":"38","author":"G Giannaccare","year":"2019","unstructured":"Giannaccare G, Pellegrini M, Sebastiani S, et al. Efficacy of omega-3 fatty acid supplementation for treatment of dry eye disease: a meta-analysis of randomized clinical trials. Cornea. 2019;38:565\u201373.","journal-title":"Cornea."},{"key":"2538_CR7","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3109\/02713683.2011.631721","volume":"37","author":"JV Greiner","year":"2012","unstructured":"Greiner JV. A single LipiFlow\u00ae thermal pulsation system treatment improves meibomian gland function and reduces dry eye symptoms for 9 months. Curr Eye Res. 2012;37:272\u20138.","journal-title":"Curr Eye Res"},{"key":"2538_CR8","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1111\/cxo.13035","volume":"103","author":"R Arita","year":"2020","unstructured":"Arita R, Fukuoka S. Non-pharmaceutical treatment options for meibomian gland dysfunction. Clin Exp Optom. 2020;103:742\u201355.","journal-title":"Clin Exp Optom"},{"key":"2538_CR9","doi-asserted-by":"publisher","unstructured":"Vigo L, Pellegrini M, Carones F, et al. Short-term effects of a novel eye mask producing heat and vibration for the treatment of meibomian gland dysfunction: a pilot study. J Ophthalmol. 2021. https:\/\/doi.org\/10.1155\/2021\/1370002.","DOI":"10.1155\/2021\/1370002"},{"key":"2538_CR10","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1089\/pho.2016.4139","volume":"34","author":"D Li","year":"2016","unstructured":"Li D, Lin SB, Cheng B. Intense pulsed light: from the past to the future. Photomed Laser Surg. 2016;34:435\u201347.","journal-title":"Photomed Laser Surg"},{"key":"2538_CR11","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.2147\/OPTH.S139894","volume":"11","author":"SJ Dell","year":"2017","unstructured":"Dell SJ. Intense pulsed light for evaporative dry eye disease. Clin Ophthalmol. 2017;11:1167\u201373.","journal-title":"Clin Ophthalmol"},{"key":"2538_CR12","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ajo.2017.08.021","volume":"183","author":"R Liu","year":"2017","unstructured":"Liu R, Rong B, Tu P, et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. Am J Ophthalmol. 2017;183:81\u201390.","journal-title":"Am J Ophthalmol"},{"key":"2538_CR13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2147\/OPTO.S217639","volume":"11","author":"G Giannaccare","year":"2019","unstructured":"Giannaccare G, Taroni L, Senni C, et al. Intense pulsed light therapy in the treatment of Meibomian gland dysfunction: current perspectives. Clin Optom (Auckl). 2019;11:113\u201326.","journal-title":"Clin Optom (Auckl)"},{"key":"2538_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1089\/pho.2014.3819","volume":"33","author":"R Toyos","year":"2015","unstructured":"Toyos R, McGill W, Briscoe D. Intense pulsed light treatment for dry eye disease due to meibomian gland dysfunction; a 3-year retrospective study. Photomed Laser Surg. 2015;33:41\u20136.","journal-title":"Photomed Laser Surg"},{"key":"2538_CR15","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jcjo.2016.01.005","volume":"51","author":"PK Gupta","year":"2016","unstructured":"Gupta PK, Vora GK, Matossian C, et al. Outcomes of intense pulsed light therapy for treatment of evaporative dry eye disease. Can J Ophthalmol. 2016;51:249\u201353.","journal-title":"Can J Ophthalmol"},{"key":"2538_CR16","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1097\/ICO.0000000000000735","volume":"35","author":"S Vegunta","year":"2016","unstructured":"Vegunta S, Patel D, Shen JF. Combination therapy of intense pulsed light therapy and meibomian gland expression (IPL\/MGX) can improve dry eye symptoms and meibomian gland function in patients with refractory dry eye: a retrospective analysis. Cornea. 2016;35:318\u201322.","journal-title":"Cornea."},{"key":"2538_CR17","first-page":"1910694","volume":"2016","author":"X Jiang","year":"2016","unstructured":"Jiang X, Lv H, Song H, et al. Evaluation of the safety and effectiveness of intense pulsed light in the treatment of meibomian gland dysfunction. J Ophthalmol. 2016;2016:1910694.","journal-title":"J Ophthalmol"},{"key":"2538_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/cxo.12541","volume":"101","author":"JM Albietz","year":"2018","unstructured":"Albietz JM, Schmid KL. Intense pulsed light treatment and meibomian gland expression for moderate to advanced meibomian gland dysfunction. Clin Exp Optom. 2018;101:23\u201333.","journal-title":"Clin Exp Optom."},{"key":"2538_CR19","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1097\/ICO.0000000000001687","volume":"37","author":"R Arita","year":"2018","unstructured":"Arita R, Mizoguchi T, Fukuoka S, et al. Multicenter study of intense pulsed light therapy for patients with refractory meibomian gland dysfunction. Cornea. 2018;37:1566\u201371.","journal-title":"Cornea."},{"key":"2538_CR20","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.oftal.2019.03.009","volume":"94","author":"LF Mej\u00eda","year":"2019","unstructured":"Mej\u00eda LF, Gil JC, Jaramillo M. Intense pulsed light therapy: a promising complementary treatment for dry eye disease. Arch Soc Esp Oftalmol. 2019;94:331\u20136.","journal-title":"Arch Soc Esp Oftalmol"},{"key":"2538_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-37186-2","volume":"9","author":"M Choi","year":"2019","unstructured":"Choi M, Han SJ, Ji YW, et al. Meibum Expressibility improvement as a therapeutic target of intense pulsed light treatment in meibomian gland dysfunction and its association with tear inflammatory cytokines. Sci Rep. 2019;9:1\u20138.","journal-title":"Sci Rep"},{"key":"2538_CR22","doi-asserted-by":"publisher","unstructured":"Vigo L, Giannaccare G, Sebastiani S, et. al. Intense pulsed light for the treatment of dry eye owing to Meibomian gland dysfunction. J Vis Exp 2019. DOI: https:\/\/doi.org\/10.3791\/57811.","DOI":"10.3791\/57811"},{"key":"2538_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4103\/jovr.jovr_12_18","volume":"14","author":"SA Ahmed","year":"2019","unstructured":"Ahmed SA, Taher IME, Ghoneim DF, et al. Effect of intense pulsed light therapy on tear proteins and lipids in meibomian gland dysfunction. J Ophthalmic Vis Res. 2019;14:3\u201310.","journal-title":"J Ophthalmic Vis Res"},{"key":"2538_CR24","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3390\/diagnostics9040147","volume":"9","author":"L Vigo","year":"2019","unstructured":"Vigo L, Taroni L, Bernabei F, et al. Ocular surface workup in patients with Meibomian gland dysfunction treated with intense regulated pulsed light. Diagnostics (Basel). 2019;9:147.","journal-title":"Diagnostics (Basel)"},{"key":"2538_CR25","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1167\/iovs.14-15764","volume":"56","author":"JP Craig","year":"2015","unstructured":"Craig JP, Chen YH, Turnbull PRK. Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 2015;56:1965\u201370.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2538_CR26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/ICL.0000000000000711","volume":"47","author":"X Yan","year":"2021","unstructured":"Yan X, Hong J, Jin X, et al. The efficacy of intense pulsed light combined with Meibomian gland expression for the treatment of dry eye disease due to Meibomian gland dysfunction: a multicenter. Randomized Controlled Trial Eye Contact Lens. 2021;47:45\u201353.","journal-title":"Randomized Controlled Trial Eye Contact Lens"},{"key":"2538_CR27","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s40123-020-00304-3","volume":"9","author":"L Valencia-Nieto","year":"2020","unstructured":"Valencia-Nieto L, Novo-Diez A, Blanco-Vazquez M, et al. Therapeutic instruments targeting meibomian gland dysfunction. Ophthalmol Ther. 2020;9:797\u2013807.","journal-title":"Ophthalmol Ther"},{"key":"2538_CR28","first-page":"CD013559","volume":"3","author":"S Cote","year":"2020","unstructured":"Cote S, Zhang AC, Ahmadzai V, et al. Intense pulsed light (IPL) therapy for the treatment of meibomian gland dysfunction. Cochrane Database Syst Rev. 2020;3:CD013559.","journal-title":"Cochrane Database Syst Rev"},{"key":"2538_CR29","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12886-019-1219-6","volume":"19","author":"X Huang","year":"2019","unstructured":"Huang X, Qin Q, Wang L, et al. Clinical results of Intraductal Meibomian gland probing combined with intense pulsed light in treating patients with refractory obstructive Meibomian gland dysfunction: a randomized controlled trial. BMC Ophthalmol. 2019;19:211.","journal-title":"BMC Ophthalmol"},{"key":"2538_CR30","doi-asserted-by":"publisher","first-page":"993","DOI":"10.2147\/OPTH.S213664","volume":"13","author":"K Stonecipher","year":"2019","unstructured":"Stonecipher K, Abell TG, Chotiner B, et al. Combined low level light therapy and intense pulsed light therapy for the treatment of meibomian gland dysfunction. Clin Ophthalmol. 2019;13:993\u20139.","journal-title":"Clin Ophthalmol"},{"key":"2538_CR31","doi-asserted-by":"publisher","unstructured":"Giannaccare G, Pellegrini M, Carnovale Scalzo G, et al. Low level therapy versus intense pulsed light for the treatment of Meibomian gland dysfunction: preliminary results from a prospective randomized comparative study. Cornea. 2021. https:\/\/doi.org\/10.1155\/2021\/1370001.","DOI":"10.1155\/2021\/1370001"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-022-02538-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-022-02538-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-022-02538-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T09:03:18Z","timestamp":1658221398000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-022-02538-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,19]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2538"],"URL":"https:\/\/doi.org\/10.1186\/s12886-022-02538-0","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,19]]},"assertion":[{"value":"25 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study followed the tenets of the Declaration of Helsinki for research involving human subjects. This study protocol was reviewed and approved by Comitato Etico Regione Calabria \u2013 Sezione Area Centro. Written informed consent was obtained from all participants after the nature and possible consequences of the study had been explained to them.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"313"}}